Batch fabrication and compact integration of customized multispectral filter arrays towards snapshot imaging.

Snapshot multispectral imaging (MSI) has been widely employed in the rapid visual inspection by virtues of the non-invasive detection mode and short integration time. As the critical functional elements of snapshot MSI, narrowband, customizable, and pixel-level multispectral filter arrays (MSFAs) that are compatible with imaging sensors are difficult to be efficiently manufactured. Meanwhile, monolithically integrating MSFAs into snapshot multispectral imagers still remains challenging considering the strict alignment precision. Here, we propose a cost-efficient, wafer-level, and customized approach for fabricating transmissive MSFAs based on Fabry-Perot structures, both in the pixel-level and window-tiled configuration, by utilizing the conventional lithography combined with the deposition method. The MSFA chips own a total dimension covering the area of 4.8 mm × 3.6 mm with 4 × 4 bands, possessing the capability to maintain narrow line widths (∼25 nm) across the whole visible frequencies. After the compact integration with the imaging sensor, the MSFAs are validated to be effective in filtering and target identification. Our proposed fabrication method and imaging mode show great potentials to be an alternative to MSFAs production and MSI, by reducing both complexity and cost of manufacturing, while increasing flexibility and customization of imaging system.

The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease.

Adequate vitamin D levels may promote cardiovascular health by improving endothelial function and down-regulating inflammation. The objective of this pilot trial was to investigate the effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease (CAD). Using a double-blind placebo wait-list control design, 90 subjects with CAD and vitamin D deficiency (< 20 ng/ml) were randomized 1:1 to 50,000 IU of oral ergocalciferol or placebo weekly for 12 weeks. Endothelial function (reactive hyperemia peripheral arterial tonometry, RH-PAT), circulating adhesion molecules, and pro-inflammatory cytokines were measured at baseline and 12 weeks. The median increase in serum 25-vitamin D from baseline was 26 ± 17 ng/ml in the active group and 4 ± 8 ng/ml in the placebo group (between-group difference = 22 ng/ml, p < 0.001). The median within-subject change in RH-PAT score was 0.13 ± 0.73 with active treatment and -0.04 ± 0.63 with placebo (between-group difference = 0.17, p = 0.44). Within-group and between-group differences in intercellular adhesion molecule levels were greater with placebo (between-group difference = 6 ng/ml, p = 0.048). Vascular cell adhesion molecule levels decreased in both groups by a similar magnitude (median difference between groups = 8.5 ng/ml, p = 0.79). There was no difference between groups in magnitude of reduction in interleukin (IL)-12 (-8.6 ng/ml, p = 0.72) and interferon-gamma (0.52 ng/ml, p = 0.88). No significant differences in blood pressure, e-selectin, high-sensitivity c-reactive protein, IL-6 or the chemokine CXCL-10 were found with treatment. In conclusion, repleting vitamin D levels in subjects with CAD failed to demonstrate any benefits on surrogate markers of cardiovascular health. These results question the role of vitamin D supplementation in modifying cardiovascular disease.